^
Association details:
| Biomarker: | CDK4 amplification |
|---|---|
| Cancer: | Osteosarcoma |
| Drug: | Ibrance (palbociclib) (CDK4/6 inhibitor) + Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1784P - Targeting FGFR signaling with FGFR inhibitor-based regimens: UCSD molecular tumor board experience
Published date:
09/13/2021
Excerpt:
The patient with the longest duration of benefit (PFS: 31months, OS: 52 months) had osteosarcoma including CDK4 amp treated with palbociclib (targeting cell cycle pathway) and lenvatinib (targeting FGFR pathway).